Biogen Reportedly Prepares to Acquire Apellis Pharmaceuticals, Targeting Ophthalmology and Rare Disease Assets

Bloomberg reports Biogen is preparing to acquire Apellis for $41 per share plus a contingent value right (CVR), a significant premium aimed at securing future growth.

The acquisition is driven by Biogen's need to offset declining revenues and Apellis's strong long-term data for its eye disease drug, SYFOVRE, and its rare disease treatment, EMPAVELI.

Key events leading to the deal include Apellis's positive clinical data, strategic board appointments, and Biogen's stated focus on M&A to bolster its product pipeline.

Bloomberg has reported that biopharmaceutical giant Biogen is preparing to acquire Apellis Pharmaceuticals in a deal that could reshape parts of the ophthalmology and rare disease markets.

The proposed deal is valued at approximately $5.24 billion, or $41 per share in cash, which represents a nearly 140% premium over Apellis's recent closing price. It also includes a Contingent Value Right (CVR), an additional payment to shareholders if certain future milestones are met. This structure helps bridge the valuation gap between the two companies, sharing both the risks and rewards of Apellis's promising drug pipeline.

So, why is this happening now? The story has two sides. First, Biogen is facing declining revenue from its older multiple sclerosis drugs and has openly stated its strategy is to use mergers and acquisitions (M&A) to buy new growth. Apellis fits this need perfectly. It has two key products: SYFOVRE, a treatment for an eye condition called Geographic Atrophy (GA), and EMPAVELI, which treats rare kidney diseases. These are durable, high-potential assets.

Second, Apellis has become an increasingly attractive target. In February 2026, the company released impressive five-year data for SYFOVRE, showing it could significantly delay disease progression. This long-term data strengthened the drug's value proposition immensely. Furthermore, Apellis made a strategic move in early March by appointing a former Pfizer R&D head to its board, a classic signal that a company is preparing for a potential sale by bolstering its credibility for a buyer's due diligence.

This potential acquisition didn't happen in a vacuum. The market for GA treatments is competitive, with Astellas's drug IZERVAY also vying for market share. This competitive pressure often encourages consolidation, as larger companies can better leverage their scale and resources. From a regulatory standpoint, the deal is not expected to face major antitrust hurdles, as Biogen has a very small presence in the ophthalmology space, reducing concerns about market monopolization.

Contingent Value Right (CVR): A financial instrument that gives shareholders the right to receive additional payments if the company achieves specific milestones, such as a drug receiving regulatory approval or hitting a sales target.
Geographic Atrophy (GA): An advanced form of age-related macular degeneration that causes progressive and irreversible vision loss.
M&A (Mergers & Acquisitions): The process of combining two companies into one, or one company taking over another, often to achieve growth, gain new technologies, or enter new markets.

Biogen Reportedly Prepares to Acquire Apellis Pharmaceuticals, Targeting Ophthalmology and Rare Disease Assets

Bloomberg reports Biogen is preparing to acquire Apellis for $41 per share plus a contingent value right (CVR), a significant premium aimed at securing future growth.

The acquisition is driven by Biogen's need to offset declining revenues and Apellis's strong long-term data for its eye disease drug, SYFOVRE, and its rare disease treatment, EMPAVELI.

Key events leading to the deal include Apellis's positive clinical data, strategic board appointments, and Biogen's stated focus on M&A to bolster its product pipeline.

Bloomberg has reported that biopharmaceutical giant Biogen is preparing to acquire Apellis Pharmaceuticals in a deal that could reshape parts of the ophthalmology and rare disease markets.

Contingent Value Right (CVR): A financial instrument that gives shareholders the right to receive additional payments if the company achieves specific milestones, such as a drug receiving regulatory approval or hitting a sales target.
Geographic Atrophy (GA): An advanced form of age-related macular degeneration that causes progressive and irreversible vision loss.
M&A (Mergers & Acquisitions): The process of combining two companies into one, or one company taking over another, often to achieve growth, gain new technologies, or enter new markets.